Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

A Study of RGX-202-01 as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies

A Study of RGX-202-01 as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies
Conditions:   Gastrointestinal Cancer;   Gastrointestinal Neoplasms;   Colorectal Cancer;   Colorectal Neoplasms;   Colorectal Carcinoma;   Gastric Cancer;   Gastric Neoplasm;   Pancreatic Cancer;   Pancreatic Neoplasm
Interventions:   Drug: RGX-202-01;   Drug: FOLFIRI;   Drug: Bevacizumab
Sponsor:   Rgenix, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 12, 2020 / by / in
Comments